Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06962332 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)
A Phase 1 study of Hepatic Impairment and Moderate Hepatic Impairment, sponsored by Exelixis.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 2
- Study locations
NCT06962332: Recruiting Phase 1 study of Hepatic Impairment and Moderate Hepatic Impairment, sponsored by Exelixis.
NCT06962332 is a Phase 1 study of Hepatic Impairment and Moderate Hepatic Impairment that is actively recruiting participants, run by Exelixis. The registered enrollment target is 20 participants, below the 36-participant average among 48 other Hepatic Impairment trials with a reported enrollment target (44% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06962332, a Phase 1 study of Hepatic Impairment and Moderate Hepatic Impairment, is actively recruiting participants, sponsored by Exelixis.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
The primary purpose of this study is to evaluate the plasma PK of zanzalintinib following a single dose in participants with moderate liver dysfunction compared to matched healthy participants with normal liver function.
Conditions Studied
Interventions
- DRUG Zanzalintinib
Study Locations (2)
Florida
- Exelixis Clinical Site #1 - Orlando
Texas
- Exelixis Clinical Site #2 - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-05-13 |
| Est. Completion | 2026-04 |
| Phase | Phase 1 |
What NCT06962332 shows while recruiting
NCT06962332 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 36-participant average among 48 other Hepatic Impairment trials with a reported enrollment target (44% lower).
The record links to 2 conditions, with Hepatic Impairment appearing as the primary indexed condition, and to 1 intervention - of which Zanzalintinib is the first listed.
NCT06962332 reports a single indexed study location in Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT06962332 about?
NCT06962332 is a clinical study titled "Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)". The primary purpose of this study is to evaluate the plasma PK of zanzalintinib following a single dose in participants with moderate liver dysfunction compared to matched healthy participants with normal liver function.
What is the current status of trial NCT06962332?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2025-05-13. Estimated completion is 2026-04.
What conditions does trial NCT06962332 study?
This clinical trial studies the following conditions: Hepatic Impairment, Moderate Hepatic Impairment.
What interventions are being tested in trial NCT06962332?
The interventions under investigation include: Zanzalintinib (DRUG).
Who is sponsoring clinical trial NCT06962332?
This trial is sponsored by Exelixis, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06962332 being conducted?
This trial has 2 study locations across Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatic Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06962332's enrollment target sits among peer trials
20 40th of 48 higher than 8 of 48 other Hepatic Impairment trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatic Impairment trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
RECRUITING · Phase 1
-
An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage
RECRUITING · Phase 1
-
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function
RECRUITING · Phase 1
-
A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems
RECRUITING · Phase 1
-
Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease
RECRUITING · Phase 1
-
A Study of Calderasib (MK-1084) in Participants With Hepatic Impairment and Healthy Volunteers (MK-1084-017)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI